メチシリン耐性黄色ブドウ球菌治療薬の市場：薬剤タイプ、投与経路、販売チャネル別-2024-2030年の世界予測

メチシリン耐性黄色ブドウ球菌治療薬市場規模は2023年に20億9,000万米ドルと推計され、2024年には22億1,000万米ドルに達し、CAGR 6.39％で2030年には32億2,000万米ドルに達すると予測されます。

メチシリン耐性黄色ブドウ球菌（MRSA）治療薬は、黄色ブドウ球菌として知られる細菌が引き起こす感染症の治療に使用される特殊な抗生物質のカテゴリーを指します。MRSA治療薬の必要性は、特に病院や介護施設などのヘルスケア環境においてMRSA感染症が増加していることから生じています。MRSA治療薬の必要性を高める主な要因としては、院内感染件数の増加、このような感染症にかかりやすい高齢者人口の増加、MRSAの診断と治療を容易にするヘルスケア・インフラの進歩などが挙げられます。しかし、これらの薬剤が広く、時には不適切に使用されることによる抗生物質耐性の出現は、大きな課題となっています。時間の経過とともに、細菌は抗生物質の効果に抵抗するように進化し、感染症の治療を困難にし、"スーパーバグ "の発生につながる可能性があります。さらに、バクテリオファージ療法、ワクチン、革新的な抗菌素材など、新たな抗生物質や代替治療法の発見を目指した研究開発が進められており、MRSAに対する武器が広がることが期待されています。さらに、予防対策への関心の高まりと、タイムリーで的確な治療を可能にする迅速診断検査の開発が、MRSA治療薬市場の成長にさらに貢献すると期待されています。

薬剤の種類MRSAの治療に有効なダプトマイシンの採用が進む

セフタロリンはセファロスポリン系として知られる抗生物質の一種で、MRSAに有効な新世代の抗生物質です。この抗生物質は細菌の生存に重要な細胞壁の合成を阻害します。メチシリン耐性菌を含む多くの細菌を効果的に標的とするため、MRSA感染症の治療に貴重な選択肢となります。ダプトマイシンはリポペプチド系抗生物質であり、細菌の細胞膜と相互作用します。そのメカニズムは独特で、細胞膜電位の急速な脱分極を引き起こし、タンパク質、DNA、RNA合成の阻害につながり、結果として細菌を死滅させる。ダプトマイシンは、MRSAを含むグラム陽性菌に特異的に有効で、皮膚感染症や血流感染症に用いられます。リネゾリドはオキサゾリジノンに属する抗生物質で、特にMRSA感染症の治療に有用です。細菌のリボソームを阻害することで作用し、増殖と複製に必要な必須タンパク質の合成を阻止します。この作用は、他の抗生物質に対する耐性株を含む、いくつかのグラム陽性菌に有効です。リネゾリドは、皮膚感染症やMRSAによる肺炎など、さまざまな感染症に使用できます。

テラバンシンはリポグリコペプチド系抗生物質に分類され、細菌の細胞壁の合成を阻害し、細胞膜の電位を破壊することによって作用します。この2つの作用により、MRSAを含む複雑な皮膚・軟部組織感染症の治療に威力を発揮します。バンコマイシンと同様の作用機序を持つが、特定の耐性菌に対する活性が強化されています。バンコマイシンは、MRSA感染症の治療に使用される最も古く、最もよく知られた抗生物質の1つです。糖ペプチドクラスに属し、細菌の細胞壁合成を阻害することで機能します。バンコマイシンは、血流感染、肺炎、心内膜炎を含む重篤なMRSA感染症に対する重要な選択肢です。バンコマイシンの使用は一般的に、他の抗生物質が効かないか、耐性の懸念から不適切な場合に限られます。

販売チャネルアクセスの容易さからオンライン・チャネルへの嗜好が拡大

MRSA感染症と診断された患者やその疑いのある患者は、病院の薬局で直接薬を入手することが多いです。このチャネルは、生命を脅かす可能性のある状況下で直ちに薬剤を投与する必要があるため、好まれています。病院は、これらのクリティカルケア抗生物質を在庫し、迅速に入手できるようにしています。さらに、外来患者や慢性MRSA感染症の患者にとっては、処方されたMRSA治療薬を入手するための一次情報として小売薬局が役立ちます。小売薬局は患者や介護者にとって利便性が高いです。

オンライン・チャネルは、再注文や宅配が容易で、他に類を見ない利便性を提供します。これは、移動に問題のある患者や遠隔地に住む患者にとって特に有利です。一部のメーカーは、自社のウェブサイトを通じてMRSA治療薬を直接提供し始めています。このチャネルは特に長期処方の患者にメリットがあり、利便性と潜在的なコスト削減を提供します。さらに、eコマースの台頭により、オンライン薬局も有力なチャネルとなっています。オンライン薬局は、簡単なアクセス、比較ショッピング、宅配オプションを求める技術に精通した消費者に対応しています。

地域別インサイト

南北アメリカ地域は、高度なヘルスケアインフラとMRSA感染に対する高い認識により、MRSA治療薬の重要な市場となっています。これらの地域の消費者ニーズは、効果的で即効性のある抗生物質と副作用の少ない治療薬に集中しています。北米の顧客は、確かな臨床試験に裏打ちされた有効性が証明された医薬品を好みます。抗生物質耐性と闘うための政府と民間部門によるイニシアチブを含め、新規抗生物質と治療法を開発するための研究への投資は顕著です。米国とカナダにおける最近の特許は、より安全で効果的な抗菌薬に重点を置いた、MRSA治療の選択肢における継続的な技術革新を反映しています。欧州連合（EU）諸国は、MRSA治療薬の多様な市場を有しており、MRSAの発生を管理するための公衆衛生イニシアチブと抗生物質管理プログラムを強く重視しています。MRSA治療薬に対するニーズは、このようなスチュワードシップ・プログラムに適合する治療薬に向けられており、新規作用機序や耐性プロファイルの低さが重視されています。EU諸国における投資は活発で、官民が新しい抗生物質の研究に資金を提供しています。中東とアフリカでは、MRSA治療薬の市場開拓の度合いが異なっており、中東ではUAEやサウジアラビアなどの国々の医療制度がより進んでいます。両地域とも、抗生物質耐性の増加により、効果的なMRSA治療薬に対する需要が高まっています。これらの地域での取り組みには、ヘルスケアインフラの改善、一般市民の意識向上キャンペーン、地域のMRSA株の遺伝子プロファイルに合わせた治療法の研究への投資などが含まれます。中国、日本、インドはアジア太平洋地域の主要市場であり、それぞれ消費者のニーズや購買行動が異なります。中国とインドでは、MRSA感染の急増により、手頃な価格で利用しやすい治療オプションの必要性が浮き彫りになっています。両国とも抗生物質の研究開発能力の強化に注力しており、中国は新薬開発に多額の投資を行い、インドはMRSA抗生物質を含むジェネリック医薬品の生産を強化しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、メチシリン耐性黄色ブドウ球菌治療薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、メチシリン耐性黄色ブドウ球菌治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.メチシリン耐性黄色ブドウ球菌治療薬市場の市場規模および予測は？

2.メチシリン耐性黄色ブドウ球菌治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.メチシリン耐性黄色ブドウ球菌治療薬市場の技術動向と規制枠組みは？

4.メチシリン耐性黄色ブドウ球菌治療薬市場における主要ベンダーの市場シェアは？

5.メチシリン耐性黄色ブドウ球菌治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • メチシリン耐性黄色ブドウ球菌による感染症の蔓延が増加
    • 民間および公共部門によるヘルスケア分野への投資増加
  • 抑制要因
    • メチシリン耐性黄色ブドウ球菌治療薬配合に使用される原材料の変動コスト
  • 機会
    • 新規開発に向けた研究開発活動を継続中メチシリン耐性黄色ブドウ球菌治療薬
    • メチシリン耐性黄色ブドウ球菌治療薬の特許失効件数の増加
  • 課題
    • 時間がかかり、厳格な規制承認プロセス
• 市場セグメンテーション分析
  • 薬剤タイプ：MRSAの効果的な治療のためのダプトマイシンの採用の進展
  • 販売チャネル：アクセスの容易さからオンラインチャネルへの嗜好が拡大
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 メチシリン耐性黄色ブドウ球菌治療薬の市場薬剤別

• セフタロリン
• ダプトマイシン
• リネゾリド
• テラヴァンシン
• バンコマイシン

第7章 メチシリン耐性黄色ブドウ球菌治療薬の市場：投与経路別

• オーラル
• 非経口

第8章 メチシリン耐性黄色ブドウ球菌治療薬の市場：販売チャネル別

• オフライン
• オンライン

第9章 南北アメリカのメチシリン耐性黄色ブドウ球菌治療薬の市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のメチシリン耐性黄色ブドウ球菌治療薬の市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのメチシリン耐性黄色ブドウ球菌治療薬の市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • 英国政府、世界の薬剤耐性監視への戦略的投資、アジアとアフリカの保健システムの強化
  • バシリア社、MRSA対策の新抗生物質セフトビプロールのFDA承認を申請
  • 小児抗生物質へのアクセス向上を目的としたメリンタ・セラピューティクスに対するBARDAの戦略的資金提供イニシアチブ
• 戦略分析と提言

第13章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET DYNAMICS
• FIGURE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TELAVANCIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TELAVANCIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 38. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 39. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 40. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 41. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 42. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 43. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 44. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 45. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 46. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 47. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 48. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 49. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 50. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 51. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 52. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 53. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 54. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 55. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 56. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 57. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 58. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 59. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 60. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 61. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 62. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 63. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 64. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 65. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 66. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 67. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 68. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 69. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 70. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 71. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 72. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 73. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 74. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 75. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 76. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 77. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 78. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 79. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 80. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 81. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 82. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 83. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 84. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 85. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 86. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 87. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 88. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 89. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 90. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 92. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 94. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 96. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 98. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 99. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 100. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 101. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 102. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 103. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 104. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 105. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 106. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 107. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 108. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 109. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 110. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 111. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 112. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 113. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 114. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 115. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 116. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 117. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 118. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 119. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 120. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 121. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 122. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 123. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 124. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 125. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 126. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 127. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 128. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 129. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 130. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 131. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 132. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 133. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 134. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 135. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 136. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 137. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 138. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 139. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 140. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 141. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 142. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 143. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 144. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 145. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 146. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 147. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 148. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 149. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 150. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 151. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 152. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 153. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 154. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 155. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 156. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 157. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 158. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 159. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 160. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 161. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 162. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 163. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 164. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 166. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 167. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 168. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 170. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 171. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 172. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 173. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 174. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 175. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 176. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 177. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 178. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 179. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 180. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 181. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 182. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 183. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 184. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 185. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 186. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 187. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 188. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 189. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 190. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 191. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 192. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 193. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 194. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 205. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 206. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 207. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 208. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 209. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 210. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 211. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 212. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 213. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 214. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 215. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 216. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 217. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 218. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 219. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 220. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 221. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 222. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 223. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 224. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 225. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 226. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 227. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 228. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 229. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 230. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 231. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 232. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 233. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 234. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 235. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 236. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 237. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 238. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 239. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 240. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 241. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 242. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 243. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 244. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 245. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 246. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 247. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 248. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 249. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 250. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 251. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 252. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 253. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 254. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 255. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 256. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 257. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
• TABLE 258. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
• TABLE 259. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 260. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 261. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
• TABLE 262. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
• TABLE 263. NETHERLANDS METHICILL

[188 Pages Report] The Methicillin-Resistant Staphylococcus Aureus Drugs Market size was estimated at USD 2.09 billion in 2023 and expected to reach USD 2.21 billion in 2024, at a CAGR 6.39% to reach USD 3.22 billion by 2030.

Methicillin-resistant Staphylococcus Aureus (MRSA) drugs refer to a specialized category of antibiotics that are used to treat infections caused by a type of bacteria known as Staphylococcus aureus, which has become resistant to many of the antibiotics traditionally used to treat bacterial infections, including methicillin. The necessity for MRSA drugs arises from the increasing prevalence of MRSA infections, particularly in healthcare settings such as hospitals and nursing homes, where infections can be severe and spread quickly. Key factors driving the need for their use include the rising number of hospital-acquired infections, the growing elderly population who are more susceptible to such infections, and the advancement of healthcare infrastructure that facilitates better diagnosis and treatment of MRSA. However, the emergence of antibiotic resistance due to widespread and sometimes inappropriate use of these drugs poses a significant challenge. Over time, bacteria can evolve to resist the effects of antibiotics, making infections harder to treat and leading to the development of "superbugs." Furthermore, the ongoing research and development aimed at discovering new antibiotics and alternative treatments, such as bacteriophage therapy, vaccines, and innovative antibacterial materials, promise to broaden the arsenal against MRSA. Additionally, the increasing focus on preventive measures and the development of rapid diagnostic tests to enable timely and precise treatment are expected to contribute further to the growth of the MRSA drugs market.

Agent Type: Evolving adoption of daptomycin for effective treatment of MRSA

Ceftaroline is part of a class of antibiotics known as cephalosporins and represents a newer generation that is effective against MRSA. This antibiotic disrupts the bacterial cell wall synthesis, which is crucial for the bacteria's survival. It effectively targets many bacteria, including methicillin-resistant ones, making it a valuable option for treating MRSA infections. Daptomycin is a lipopeptide antibiotic, which means it interacts with the bacterial cell membranes. Its mechanism is unique; it causes rapid depolarization of the cell membrane potential, leading to inhibition of protein, DNA, and RNA synthesis, resulting in bacterial death. Daptomycin is specifically effective against gram-positive bacteria, including MRSA, and is used for skin and bloodstream infections. Linezolid belongs to the oxazolidinone class of antibiotics and is especially useful in treating MRSA infections. It operates by interfering with the bacterial ribosome, preventing the synthesis of essential proteins needed for growth and replication. This action is effective against several gram-positive bacteria, including strains resistant to other antibiotics. Linezolid can be used for various infections, including skin infections and pneumonia caused by MRSA.

Telavancin is classified as a lipoglycopeptide antibiotic, which works by inhibiting the synthesis of the bacterial cell wall and disrupting the cell membrane's electrical potential. This dual action makes it a potent option for treating complicated skin and soft tissue infections, including those caused by MRSA. It has a similar mode of action to vancomycin but with enhanced activity against certain resistant bacteria. Vancomycin is one of the oldest and most well-known antibiotics used to treat MRSA infections. It belongs to the glycopeptide class, functioning by inhibiting bacterial cell wall synthesis. Vancomycin is a critical option for serious MRSA infections, including bloodstream infections, pneumonia, and endocarditis. Its use is generally reserved for cases where other antibiotics have failed or are inappropriate due to resistance concerns.

Sales Channel: Expanding preference towards online channels due to easy access

Patients diagnosed with or suspected of having MRSA infections often access medications directly through hospital pharmacies. This channel is preferred due to the immediate need for administering drugs in potentially life-threatening situations. Hospitals stock these critical care antibiotics to ensure quick availability. In addition, for outpatients or those managing chronic MRSA infections, retail pharmacies serve as a primary source for obtaining prescribed MRSA drugs. They offer convenience for patients and caregivers.

Online channels offer unmatched convenience, allowing for easy reordering and home delivery. This is particularly advantageous for patients with mobility issues or those residing in remote areas. Some manufacturers have started offering MRSA drugs directly through their websites. This channel particularly benefits patients with long-term prescriptions, offering convenience and potentially lower costs. Moreover, with the rise of e-commerce, online pharmacies have become a viable channel. They cater to tech-savvy consumers looking for easy access, comparison shopping, and home delivery options.

Regional Insights

The Americas region represents a significant market for MRSA drugs, driven by advanced healthcare infrastructure and high awareness of MRSA infections. The consumer needs in these regions focus on effective, fast-acting antibiotics and treatments with minimal side effects. Customers in North America prefer drugs with proven efficacy, backed by robust clinical trials. There has been a notable investment in research for developing novel antibiotics and therapies, including initiatives by the government and private sectors to combat antibiotic resistance. Recent patents in the US and Canada reflect ongoing innovation in MRSA treatment options, emphasizing safer and more effective antibacterial agents. The European Union (EU) countries have a diverse market for MRSA drugs, strongly emphasizing public health initiatives and antibiotic stewardship programs to manage MRSA outbreaks. The need for MRSA drugs is geared towards treatments compatible with these stewardship programs, highlighting a preference for novel mechanisms of action and lower resistance profiles. Investment in EU countries is robust, with public and private sectors funding research into new antibiotics. The Middle East and Africa show varying levels of market development for MRSA drugs, with the Middle East having more advanced healthcare systems in countries like the UAE and Saudi Arabia. Both regions have a growing demand for effective MRSA treatments due to increasing antibiotic resistance. Efforts in these regions include improving healthcare infrastructure, public awareness campaigns, and investments in research to tailor treatments to the genetic profiles of local MRSA strains. China, Japan, and India represent key Asian Pacific markets, each with distinct consumer needs and purchasing behaviors. In China and India, the rapid increase in MRSA infections has underscored the need for affordable and accessible treatment options. Both countries are focusing on bolstering their antibiotic research and development capabilities, with China investing heavily in new drug development and India enhancing its generic drug production to include MRSA antibiotics.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Methicillin-Resistant Staphylococcus Aureus Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Methicillin-Resistant Staphylococcus Aureus Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Methicillin-Resistant Staphylococcus Aureus Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Aridis Pharmaceuticals Inc., Armata Pharmaceuticals, Inc., AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bausch Health Companies Inc., Baxter International Inc., Becton, Dickinson and Company, Cardinal Health, Inc., Cumberland Pharmaceuticals Inc., Debiopharm SA, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, GlaxoSmithKline PLC, Innovation Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Nabriva Therapeutics GMBH, Novartis AG, Paratek Pharmaceuticals, Inc., Pfizer Inc., R-Biopharm AG, Shionogi Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries ltd, and Theravance Biopharma, Inc..

Market Segmentation & Coverage

This research report categorizes the Methicillin-Resistant Staphylococcus Aureus Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Agent Type
  • Ceftaroline
  • Daptomycin
  • Linezolid
  • Telavancin
  • Vancomycin

• Route of Administration
  • Oral
  • Parenteral

• Sales Channel
  • Offline
    • Hospitals Pharmacies
    • Retail Pharmacies

• Online

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Methicillin-Resistant Staphylococcus Aureus Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Methicillin-Resistant Staphylococcus Aureus Drugs Market?

3. What are the technology trends and regulatory frameworks in the Methicillin-Resistant Staphylococcus Aureus Drugs Market?

4. What is the market share of the leading vendors in the Methicillin-Resistant Staphylococcus Aureus Drugs Market?

5. Which modes and strategic moves are suitable for entering the Methicillin-Resistant Staphylococcus Aureus Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of infections associated with methicillin-resistant staphylococcus aureus
    • 5.1.1.2. Rising investment in healthcare sector by private & public sector
  • 5.1.2. Restraints
    • 5.1.2.1. Fluctuating cost of raw materials used in methicillin-resistant staphylococcus aureus drugs formulations
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research & development activities to develop novel methicillin-resistant staphylococcus aureus drugs
    • 5.1.3.2. Increasing number of patent expiration of methicillin-resistant staphylococcus aureus drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Time consuming and strict regulatory approval processes
• 5.2. Market Segmentation Analysis
  • 5.2.1. Agent Type: Evolving adoption of daptomycin for effective treatment of MRSA
  • 5.2.2. Sales Channel: Expanding preference towards online channels due to easy access
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Agent Type

• 6.1. Introduction
• 6.2. Ceftaroline
• 6.3. Daptomycin
• 6.4. Linezolid
• 6.5. Telavancin
• 6.6. Vancomycin

7. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Route of Administration

• 7.1. Introduction
• 7.2. Oral
• 7.3. Parenteral

8. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Sales Channel

• 8.1. Introduction
• 8.2. Offline
• 8.3. Online

9. Americas Methicillin-Resistant Staphylococcus Aureus Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. UK Government's Strategic Investment in Global AMR Surveillance, Strengthening Health Systems Across Asia and Africa
  • 12.3.2. Basilea Seeks FDA Approval for New MRSA-Fighting Antibiotic Ceftobiprole
  • 12.3.3. BARDA's Strategic Funding Initiative for Melinta Therapeutics to Enhance Pediatric Antibiotic Access
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio